Compare ANGH & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANGH | KYNB |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.9M | 32.8M |
| IPO Year | 2021 | 2014 |
| Metric | ANGH | KYNB |
|---|---|---|
| Price | $3.88 | $6.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.2K | ★ 23.8K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9552.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,440,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.25 | $6.32 |
| 52 Week High | $7.89 | $9.58 |
| Indicator | ANGH | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 58.08 | 35.74 |
| Support Level | $3.09 | $6.74 |
| Resistance Level | $3.89 | $7.47 |
| Average True Range (ATR) | 0.24 | 0.43 |
| MACD | 0.04 | -0.13 |
| Stochastic Oscillator | 86.55 | 14.40 |
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. The Group's three reportable segments: Revenue from subscriptions, Revenue from advertisement, and Revenue from live events. It generates the majority of its revenue from subscriptions segment, which is comes from subscription fees. The advertisement revenue segment generated through the sale of advertising across the Group's content. Revenues from live events are generated from the sale of tickets, food and beverage & sponsorship. It derives maximum revenue from KSA.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.